AG
CLVS

Artal Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Artal Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,000,000
Closed -$7.57M – 141
2020
Q1 		$6.36M Hold
1,000,000
– – 0.27% 61
2019
Q4 		$10.4M Buy
1,000,000
+500,000
+100% +$3.64M 0.4% 44
2019
Q3 		$1.97M Buy
+500,000
New +$4.04M 0.08% 97
2018
Q1 		– Sell
-100,000
Closed -$5.83M – 139
2017
Q4 		$6.8M Sell
100,000
-15,000
-13% -$1.05M 0.1% 59
2017
Q3 		$9.48M Buy
115,000
+90,000
+360% +$7.13M 0.16% 44
2017
Q2 		$2.34M Buy
+25,000
New +$1.53M 0.04% 92
2017
Q1 		– Sell
-50,000
Closed -$2.22M – 111
2016
Q4 		$2.22M Buy
+50,000
New +$1.76M 0.05% 76

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's CLVS Position: Q2 2020 in Review

Artal Group sold out of Clovis Oncology, Inc. (CLVS) in Q2 2020, closing a stake of 1,000,000 shares — an estimated $7.57M sold.

Artal Group first reported a position in CLVS in Q4 2016 and held it in 7 quarters. The position peaked at $10.4M in Q4 2019. 158 funds tracked by Wall St. Rank hold CLVS as of Q2 2020.

  • Artal Group reported no remaining Clovis Oncology, Inc. position as of Q2 2020 after selling out during the quarter.
  • Artal Group sold 1,000,000 Clovis Oncology, Inc. shares in Q2 2020, an estimated $7.57M.
  • Artal Group first reported a position in Clovis Oncology, Inc. in Q4 2016 and held it in 7 quarters.
  • Artal Group's Clovis Oncology, Inc. position peaked at $10.4M in Q4 2019.
  • 158 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2020.

Based on Artal Group's 13F filing for Q2 2020, filed 14 Aug 2020.